Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trialYung‐Jue Bang, Narikazu Boku, Rui‐Hua Xu et al.|The Lancet Oncology|2017Cited by 291
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancerThomas Powles, Dónal Landers, Aude Fléchon et al.|Nature Medicine|2021Cited by 115
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Rodrigo A. Toledo, Charles W. Abbott et al.|Clinical Cancer Research|2025Cited by 1